Bayer CropScience Limited

BSE:506285 Stock Report

Market Cap: ₹207.1b

Bayer CropScience Future Growth

Future criteria checks 2/6

Bayer CropScience is forecast to grow earnings and revenue by 10.9% and 9.2% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 27.8% in 3 years.

Key information

10.9%

Earnings growth rate

11.90%

EPS growth rate

Chemicals earnings growth20.5%
Revenue growth rate9.2%
Future return on equity27.83%
Analyst coverage

Good

Last updated10 Apr 2026

Recent future growth updates

Recent updates

Narrative Update • May 01

506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook

Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.
Narrative Update • Apr 17

506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook

The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.
Narrative Update • Apr 02

506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
Narrative Update • Mar 19

506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook

Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).
Narrative Update • Mar 04

506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook

Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
Narrative Update • Feb 17

506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook

Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
Narrative Update • Feb 03

506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.
Narrative Update • Jan 20

506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.
Narrative Update • Jan 05

506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.
Narrative Update • Dec 21

506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year

Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.
Narrative Update • Dec 07

506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025

Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.
Narrative Update • Nov 23

506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025

Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.
User avatar
New Narrative • May 18

Seeds, Traits And Biofuels Will Unlock New Value Pools

Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.

Earnings and Revenue Growth Forecasts

BSE:506285 - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202868,6988,4827,402N/A8
3/31/202762,4927,4956,348N/A8
3/31/202656,9986,7456,730N/A8
12/31/202556,2066,704N/AN/AN/A
9/30/202555,7186,0892,5703,127N/A
6/30/202557,5665,925N/AN/AN/A
3/31/202554,7345,6802,2112,620N/A
12/31/202452,1725,207N/AN/AN/A
9/30/202451,1525,79610,25210,753N/A
6/30/202449,9486,662N/AN/AN/A
3/31/202451,0627,4059,0599,516N/A
12/31/202352,9428,030N/AN/AN/A
9/30/202353,7728,4444,0204,478N/A
6/30/202352,1197,841N/AN/AN/A
3/31/202351,3977,5825,3206,093N/A
12/31/202251,2057,524N/AN/AN/A
9/30/202250,7277,0273,0703,842N/A
6/30/202249,8596,942N/AN/AN/A
3/31/202247,3446,4531,6012,155N/A
12/31/202145,0485,545N/AN/AN/A
9/30/202144,3294,246268698N/A
6/30/202144,4944,951N/AN/AN/A
3/31/202142,6134,9316,4476,867N/A
12/31/202039,9134,627N/AN/AN/A
9/30/202039,2716,45711,55312,052N/A
6/30/202038,9185,909N/AN/AN/A
3/31/202036,0944,7456,2466,659N/A
12/31/201929,2942,864N/AN/AN/A
9/30/201928,5052,116N/A2,432N/A
6/30/201925,2561,497N/AN/AN/A
3/31/201931,7543,371N/A4,328N/A
12/31/201828,6393,045N/AN/AN/A
9/30/201827,2262,877N/AN/AN/A
6/30/201828,5053,356N/AN/AN/A
3/31/201827,1673,001N/A1,214N/A
12/31/201726,3752,769N/AN/AN/A
9/30/201728,2033,030N/AN/AN/A
6/30/201726,7962,715N/AN/AN/A
3/31/201728,1532,910N/A1,573N/A
12/31/201640,1053,323N/AN/AN/A
9/30/201632,0303,342N/AN/AN/A
6/30/201638,0273,215N/AN/AN/A
3/31/201627,8383,151N/A2,065N/A
12/31/201537,9193,278N/AN/AN/A
9/30/201538,5693,554N/AN/AN/A
6/30/201539,2223,814N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 506285's forecast earnings growth (10.9% per year) is above the savings rate (6.9%).

Earnings vs Market: 506285's earnings (10.9% per year) are forecast to grow slower than the Indian market (16.8% per year).

High Growth Earnings: 506285's earnings are forecast to grow, but not significantly.

Revenue vs Market: 506285's revenue (9.2% per year) is forecast to grow slower than the Indian market (11% per year).

High Growth Revenue: 506285's revenue (9.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 506285's Return on Equity is forecast to be high in 3 years time (27.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/09 20:03
End of Day Share Price 2026/05/08 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bayer CropScience Limited is covered by 26 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null null360 ONE Capital Market Private Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Himanshu BinaniAnand Rathi Shares and Stock Brokers Limited